AAV Structural Plasmid Design for High-Titer Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current methods for producing adeno-associated virus (AAV) vectors face challenges in achieving high yields and meeting the stringent quality and quantity demands of gene therapy, with a significant disparity between production titer and clinical requirements, limiting commercial supply.
Innovation Solution
An adeno-associated virus structural plasmid is designed with a Rep gene expression cassette and a Cap gene expression cassette in sequence, utilizing specific promoters and modified promoters and codons to enhance vector yield, incorporating a transcription termination signal, and using a three-plasmid system for high-titer virus production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional three-plasmid transient transfection system is used for AAV production, then the production process is simple and easy to operate, but the virus titer is low and cannot meet clinical demand
Solution Approach 1:
The patent divides the structural protein gene expression into separate cassettes for Rep genes and Cap genes, each with independent promoters. This segmentation allows optimized expression control for each protein type, resulting in higher viral assembly efficiency and titer while maintaining manageable system complexity
Solution Approach 2:
The patent employs specific promoter selections (PV promoter for Rep genes, CMV promoter for Cap genes) and modifies transcription termination signals to optimize gene expression parameters. These parameter changes in the plasmid construction significantly enhance viral protein production and subsequently increase AAV titer
2Quantity of substance
If virus production quantity is increased to meet clinical demand, then the supply capability improves, but the quality control and residual substance removal become more difficult
Solution Approach 1:
The patent extracts and optimizes specific functional elements from the viral genome, including the ITR sequences for replication origin and packaging signal, and separates them into distinct plasmid components. This extraction allows for controlled viral assembly and facilitates better quality control during large-scale production
Solution Approach 2:
The patent incorporates transcription termination signals and optimized promoter structures that provide built-in feedback mechanisms for controlling gene expression levels. This ensures consistent viral protein production and facilitates quality control even at scaled-up production levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified plasmid system significantly improves AAV titer and infectious activity, enabling the production of high-quality, scalable, and cost-effective AAV vectors suitable for commercial use.
Implementation Method 1
a rep gene regulated by a first promoter for transcription
Implementation Method 2
These two ITRs are the origin of replication of the viral DNA
Implementation Method 3
The protein capsid is composed of three subunits, i.e., VP1, VP2, and VP3
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The present disclosure relates to the technical field of molecular biology, and in particular to an adeno-associated virus structural plasmid capable of improving adeno-associated virus titer, which is provided with a Rep gene expression cassette and a Cap gene expression cassette in sequence in the gene expression direction. The Rep gene expression cassette comprises a rep gene regulated and transcribed by a first promoter, and a transcription termination signal fragment is arranged behind the rep gene; the Cap gene expression cassette comprises a cap gene regulated and transcribed by a second promoter, wherein the first promoter comprises any one of a P5 promoter, an RSV promoter, an MMTV promoter, a UBC promoter, and a U6 promoter, and the second promoter comprises one or more of a CMV promoter, a CBh promoter, a CAG promoter, an EF1α promoter, and an SFFV promoter.